EVER PHARMA

Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.

SMALL MOMENT. BIG DIFFERENCE.

Last month Henry had a TBI.
Today he is successful in his job again.

Quality from Austria.

Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.

EVER PHARMA

Big Problem with cognitive impairment after TBI – What to do?

The most common neurocognitive consequences[1] of TBI at all levels of severity are disturbances of



- These problems **may cause additional disturbances** (e.g. in communication)
- Cognitive impairments create **big socio-economic burdens** for patients and family members[2]

Treatment of such consequences is essential!

Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.

Take life into your own hands again!

- Improvement of memory and concentration impairment after TBI
- Faster reintegration into worklife
- Sound decision making

Figure: Single cognitive outcomes, MW, Day 90, PP

Large inferiority = 0,29; Medium inferiority = 0,36, Small inferiority = 0,44; Equality = 0,50; Small superiority = 0,56; Medium superiority = 0,64; Large superiority = 0,71

- All 3 cognition scales are **statistically significant**
- Scales show **large-sized superiority**
- **Even on day 30** already large treatment effects in Digit Span Backward test

Treat TBI patients with Cerebrolysin® as soon as possible!

The effective treatment after TBI

- Early treatment effects
- Significantly reduced depression
- Improvement of memory and concentration

Disorder	Daily dosage	Initiation of treatment	Duration of treatment
Traumatic brain injury	20 - 50 ml	as soon as possible	7 - 30 days

Title: Efficacy and safety of Cerebrolysin® in Neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial

Patients: 80 Cerebrolysin® group + 59 Placebo group = 139 patient in total

Treatment: Treatment Cycle 1 = Day 1 - 10 : 50 ml/day
Treatment Cycle 2 = Day 31 - 40 : 10 ml/day
Treatment Cycle 3 = Day 61 - 70 : 10 ml/day

1 https://www.ncbi.nlm.nih.gov/pubmed/11734103
2 Muresanu, Dafin F., et al. "Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial." Neurological Sciences (2020): 1-11

ABBREVIATED PRESCRIBING INFORMATION - Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. (Reference SPC – CCDS Version 2.0/03.06.2016)
EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria, www.everpharma.com, www.cerebrolysin.com

CERE/INT/01/2020/3